With Positive Phase III Data From Lumasiran, Alnylam On Track For Another ApprovalSeeking Alpha • 12/18/19
Biotech Succeeds With Gene-Silencing Drug — But Its Stock Rally FailsInvestors Business Daily • 12/17/19
Here's Why Momentum Investors Will Love Alnylam Pharmaceuticals (ALNY)Zacks Investment Research • 12/13/19
Alnylam Continues To Deliver On RNAi Pipeline With Alternative Treatment Option For Rare DiseaseSeeking Alpha • 12/05/19
Alnylam Pharmaceuticals, Inc. (ALNY) Shares March Higher, Can It Continue?Zacks Investment Research • 11/26/19
Alnylam Pharmaceuticals Sheds Some Light On Its Expanding Early-Stage OpportunitiesSeeking Alpha • 11/26/19
Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug ClassThe Motley Fool • 11/23/19
Alnylam Pharmaceuticals Secures Its Second Approval, And The Pipeline Is Still AttractiveSeeking Alpha • 11/21/19